Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population

Cancer Genetics and Cytogenetics

Volumn 189, Issue 2, 2009, Pages 71-76

  Paz y Miño, César ^a,b   Witte, Tania ^a   Robles, Paulo ^c   Llumipanta, William ^c   Díaz, Myriam ^d   Arévalo, Melissa ^a  

^a Biological Sciences School   (Ecuador)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^c UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^d HOSPITAL CARLOS ANDRADE MARÍN   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER INVASION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; ECUADOR; GENE FREQUENCY; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ECUADOR; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 59849121751     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.09.012     Document Type: Article

References (32)

1. Corral F., Cueva P., and Yépez J. Cancer Epidemiology in Quito and other Ecuadorian Regions (2004), National Cancer Registry (NCR), SOLCA, Quito, AH, Editorial 330 pp.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
3. Santisteban A. Cáncer en el siglo XXI. Acta Med Per 23 (2006) 112-118
4. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe 2006. Ann Oncol 18 (2007) 581-592
5. Postma R., and Schröder F.H. Screening for prostate cancer. Eur J Cancer 41 (2005) 825-833
6. Bosland M. Sex steroids and prostate carcinogenesis integrated, multifactorial working hypothesis. Ann NY Acad Sci 1089 (2006) 168-176
7. Ross R.K., Pike M.C., Coetzee G.A., Reichardt J.K.V., Yu M.C., Feigelson H., Stanczyk F.Z., Kolonel L.N., and Henderson B.E. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 58 (1998) 4497-4504
8. Singh A., Chau C.H., Price D.K., and Figg W.D. Mechanism of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract 2 (2005) 101-107
9. Hsing A.W., Chen C., Chokkalingam A.P., Gao Y.T., Dightman D.A., Nguyen H.T., Deng J., Cheng J., Sesterhenn I.A., Mostofi F.K., Stanczyk F.Z., and Reichardt J.K.V. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prev 10 (2001) 1077-1082
10. Makridakis N.M., Ross R.K., Pike M.C., Chang L., Stanczyk F.Z., Kolonel L.N., Shi C.Y., Yu M.C., Henderson B.E., and Reichardt J.K.V. A prevalent missense substitution that modulates activity of prostatic steroid 5α- reductase. Cancer Res 57 (1997) 1020-1022
11. Nam R.K., Toi A., Vesprini D., Ho M., Chu W., Harvie S., Sweet J., Trachtenberg J., Jewett M.A.S., and Narod S.A. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57 (2001) 199-204
12. Li Z., Habuchi T., Mitsumori K., Kamoto T., Kinoshitu H., Segawa T., Ogawa O., and Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urology 169 (2003) 2378-2381
13. Makridakis N.M., Ross R.K., Pike M.C., Crocitto L.E., Kolonel L.N., Pearce C.L., Henderson B.E., and Reichardt K.V. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 (1999) 975-978
14. Ribeiro M.L., Santos A., Carvalho-Salles A.B., and Hackel C. Allelic frequencies of six polymorphic markers for risk of prostate cancer. Braz J Med Biol Res 35 (2002) 205-213
15. Cicek M.S., Conti D.V., Curran A., Neville P.J., Paris P.L., Casey G., and Witte J.S. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59 (2004) 69-76
16. Jaffe J.M., Malkowicz S.B., Walker A.M., MacBride S., Peschel R., Tomaszewski J., Van Arsdalen K., Wein A.J., and Rebbeck T.R. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 60 (2000) 1626-1630
17. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., Katoh T., Kawamura J., Yatani R., and Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer 92 (2001) 683-686
18. Lamharzi N., Johnson M.M., Goodman G., Etzioni R., Weiss N.S., Dightman D.A., Barnett M., DiTommaso D., and Chen C. Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer. Int J Cancer 105 (2003) 480-483
19. Hayes V.M., Severi G., Padilla E.J.D., Morris H.A., Tilley W.A., Southey M.C., English D.R., Sutherland R.L., Hopper J.L., Boyle P., and Giles G.G. 5α-reductase type II gene variant associations with prostate cancer risk, circulating hormone levels and androgenic alopecia. Int J Cancer 120 (2006) 776-780
20. Neslund-Dudas C., Bock C.H., Monaghan K., Nock N.L., Yang J.J., Rundle A., Tang D., and Rybicki B.A. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67 (2007) 1654-1663
21. Sarma A.V., Dunn R.L., Lange L.A., Ray A., Wang Y., Lange E.M., and Cooney K.A. Genetic polymorphisms in CYP17, CYP3A4, CYPI9AI, SRD5A2, IGF-I, and IGFBP-3 and prostate cancer risk in African-American men: The flint men's health study. Prostate 68 (2008) 296-305
22. Söderström T., Wadelius M., Andersson S.O., Johansson J.E., Johansson S., Granath F., and Rane A. 5α-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12 (2002) 307-312
23. Shibata A., Garcia M.I., Cheng I., Stamey T.A., McNeal J.E., Brooks J.D., Henderson S., Yemoto C.E., and Peehl D.M. Polymorphisms in the androgen receptor and type II 5α-reductase genes and prostate cancer prognosis. Prostate 52 (2002) 269-278
24. Forrest M.S., Edwards S.M., Houlston R., Kote-Jarai Z., Key T., Allen N., Knowles M.A., Turner F., Ardern-Jones A., Murkin A., Williams S., Oram R., et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 95-102
25. Febbo P.G., Kantoff P.W., Platz E.A., Casey D., Batter S., Giovannucci E., Hennekens C.H., and Stampfer M.J. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 59 (1999) 5878-5881
26. Margiotti K., Sangiuolo F., De Luca A., Froio F., Pearce C.L., Ricci-Barbini V., Micali F., Bonafé M., Franceschi C., Dallapicola B., Novelli G., and Reichardt J.K.V. Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients. Dis Markers 16 (2000) 147-150
27. Makridakis N.M. di Salle E, Reichardt JKV. Biochemical and pharmacogenetic dissection of human steroid 5α reductase type II. Pharmacogenetics 10 (2000) 407-413
28. Loukola A., Chadha M., Penn S.G., Rank D., Conti D.V., Thompson D., Cicek M., Love B., Bivolarevic V., Yang Q., Jiang Y., Hanzel D.K., et al. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Euro J Hum Genet 12 (2004) 321-332
29. Latil A.G., Azzouzi R., Cancel G.S., Guillaume E.C., Cochan-Priollet B., Berthon P.L., and Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92 (2001) 1130-1137
30. Mononen N., Ikonen T., Syrjäkoski K., Matikainen M., Schleutker J., Tammela T.L., Koivisto P.A., and Kallioniemi O.P. A missense substitution A49T in the steroid 5-α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 84 (2001) 1344-1347
31. Leone P.E., Vega M.E., Jervis P., Pestaña A., Alonso J., and Paz-y-Miño C. Two new mutations and three novel polymorphisms in the RB1 gene in Ecuadorian patients. J Hum Genet 48 (2003) 639-641
32. Paz-y-Miño C., Arévalo M., Muñoz M.J., and Leone P.E. CYP1A1 genetic polymorphisms in Ecuador, South America. Dis Markers 21 (2005) 57-59